Eton Pharmaceuticals: FDA Extends ET-400 Review to Late May
Eton Pharmaceuticals said the Food and Drug Administration has extended by three months its review of the company's application seeking approval of its ET-400 liquid formulation of hydrocortisone.
Cherry Ventures raises a new $500M fund for early-stage and beyond, but will it be enough?
It’s sometimes said that European VC doesn’t have the firepower to compete with VCs in the U.S., which regularly raise ...